Navigation Links
Merz Launches New Online Resource for Patients with Focal Dystonias
Date:2/2/2011

GREENSBORO, N.C., Feb. 2, 2011 /PRNewswire/ -- In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias (movement disorders characterized by muscle contractions and spasms that cause twisting and repetitive movements or abnormal postures), completing simple, everyday tasks can be a difficult and challenging process.

FocalDystoniaExchange.com offers educational information about the symptoms and effects associated with focal dystonias, including cervical dystonia (also known as spasmodic torticollis) and blepharospasm, which are the most common forms of focal dystonia. The site also provides information on how people with dystonia can utilize social media tools to share their experiences and related resources with others affected by the condition. In addition, articles of interest and downloadable materials, such as a treatment journal, can be used to help guide discussion between physicians and patients in an effort to manage symptoms and optimize treatment.

Among other features, the website includes a patient journal written by Beka Serdans, R.N., founder of Care4Dystonia, Inc. (www.Care4Dystonia.org), a non-profit organization dedicated to those affected by dystonia.

"FocalDystoniaExchange.com provides a unique combination of online educational resources for patients and their families," says Serdans. "Focal dystonias are very complex movement disorders that may require treatment and lifestyle changes. As a patient and a caregiver, it is heartening to know we can help patients learn how to make these changes by sharing the real-life experiences and examples of others, and give them tools they can use to talk to their doctors about how they can manage the condition and live satisfying lives."

The new site offers various opportunities for patients and caregivers to be recognized for their ongoing dedication to the focal dystonia community. The patient stories section provides a glimpse into real-life patient experiences, and the featured community member page highlights those who are making an impact on the exchange of dystonia information through social media and networking tools. In both sections, visitors have the opportunity to submit their own personal story to potentially be highlighted on the website in the future.

"Merz Pharmaceuticals is committed to raising awareness of focal dystonias and encouraging patient dialogue, especially for lesser-known conditions such as cervical dystonia and blepharospasm," said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC. "We hope that patients and their families will benefit from this new online resource as they seek information about managing focal dystonias."

To learn more, please visit www.FocalDystoniaExchange.com and become a fan of Focal Dystonia Exchange on Facebook at www.Facebook.com/FocalDystoniaExchange.

About Dystonia

Dystonias are movement disorders in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures. These movements, which are involuntary and sometimes painful, may affect a single muscle (focal), a group of muscles such as those in the arms, legs, or neck (segmental), or even the entire body (generalized). Symptoms can be mild or severe and dystonias may be markedly disabling.

Although dystonia is thought to be rare, it is possibly undiagnosed or misdiagnosed due to lack of specific clinical criteria. While focal dystonias such as blepharospasm or cervical dystonia can affect people at any age, most people first experience symptoms in middle age.

According to an epidemiology study conducted in Rochester, Minn., focal dystonia (which includes cervical dystonia, and may be characterized by twisting of the neck, and blepharospasm, or excessive eyelid spasm) is estimated to affect 295 per million people in the U.S.

About Merz

Merz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry.

With a 102 year heritage, the Merz Group is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine. Global research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.


'/>"/>
SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017   Dynatronics Corporation (NASDAQ: ... Cynthia L. McHenry (Cyndi) as Vice ... leading Dynatronics manufacturing, distribution, and purchasing operations across ... CEO Kelvyn H. Cullimore, Jr. ... process conducted by the company as it continues ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number of advantages ... economic arguments also favor its legalization. The benefits include increased ... to legalize and regulate marijuana requires an ecosystem of support ... SING Profile ), American Cannabis Company (OTC: AMMJ), Kush Bottles, ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... ... 29, 2017 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices has recently updated its Visio Stencils library with ... and download shapes and stencils from http://www.VisioStencils.com. , New devices were ...
(Date:3/29/2017)... Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... of a growing number of cancers and is touted to be the next revolution ... treatment, thus far, has been in the form of immune checkpoint inhibitors such as ...
(Date:3/29/2017)... ... , ... AvePoint , the Microsoft Cloud expert, is pleased to announce ... at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ... and Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):